The U.S. Food and Drug Administration on August 28 approved Eli Lilly's Mounjaro, the GIP/GLP-1 receptor agonist tirzepatide, to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high cardiovascular risk. The approval makes Mounjaro the first drug in its class with a cardiovascular-risk-reduction indication, expanding a label previously limited to glycemic control.
Trial Evidence
The approval is based on the SURPASS-CVOT trial, the largest and longest tirzepatide study to date, with more than 13,000 participants across 30 countries and a median follow-up of roughly four years. The trial demonstrated an 8 percent lower rate of major adverse cardiovascular events, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke, compared with the GLP-1 receptor agonist dulaglutide, sold as Trulicity. The trial met its non-inferiority criteria but not a statistical superiority threshold.
Why It Matters
Cardiovascular disease is the leading cause of death in people with type 2 diabetes, and the approval gives physicians a metabolic agent with proven cardiovascular benefit in the highest-risk patients. Mounjaro's expanded label strengthens Eli Lilly's position in the GLP-1 market against Novo Nordisk's semaglutide, which holds a separate cardiovascular indication under the Wegovy brand for patients with obesity. The approval comes in a flurry of end-of-August FDA actions that also included the first oral therapy for dermatomyositis and new HIV single-tablet regimens.
Commercial Outlook
Analysts at Morningstar said the expanded indication could extend Mounjaro's run-rate well beyond the $20 billion in quarterly sales it posted in the first half of 2026. Lilly is investing in manufacturing capacity to address supply constraints that have limited GLP-1 availability, and the cardiovascular label gives payers additional evidence to justify coverage decisions for the drug's roughly $1,000-per-month list price.
Related Articles
FDA Approves Daraxonrasib, First RAS-Targeted Pancreatic Cancer Drug With No Mutation Test Required
The FDA on August 27 approved daraxonrasib (Rasonque, Revolution Medicines) for previously treated metastatic pancreatic adenocarcinoma, making it the first RAS-targeted drug that does not require a companion mutation test.
FDA Approves Jazz's Ziihera Plus Tislelizumab as First Bispecific HER2 Regimen for Gastric Cancer
FDA approved Jazz Pharmaceuticals' Ziihera plus Tislelizumab and chemotherapy on August 25 for first-line HER2-positive gastroesophageal adenocarcinoma, citing median OS of 26.4 vs 19.2 months and triggering a $250 million milestone to Zymeworks.
FDA Approves IMAAVY as First Ever Therapy for Warm Autoimmune Hemolytic Anemia
Johnson & Johnson's nipocalimab-aahu becomes the first FDA-approved treatment for wAIHA in adults and pediatric patients 12 and older, after a Phase 2/3 trial showed roughly 3x the durable hemoglobin response versus placebo at 24 weeks.
Comments (0)
Log in or sign up to leave a comment.
No comments yet. Be the first to share your thoughts.